scinapse is loading now...
Fatih Demirkan
Dokuz Eylül University
103Publications
11H-index
688Citations
Publications 103
Newest
Published on Feb 1, 2019in The Lancet Haematology 10.70
Anas Younes68
Estimated H-index: 68
(Memorial Sloan Kettering Cancer Center),
Nina Bhardwaj78
Estimated H-index: 78
(Icahn School of Medicine at Mount Sinai)
+ 28 AuthorsFrancesc Bosch51
Estimated H-index: 51
Summary Background Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. Methods We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the s...
1 Citations Source Cite
Published on Jan 1, 2019in Lancet Oncology 36.42
Carol Moreno24
Estimated H-index: 24
(Autonomous University of Barcelona),
Richard Greil50
Estimated H-index: 50
+ 17 AuthorsIan W. Flinn53
Estimated H-index: 53
(Sarah Cannon Research Institute)
Summary Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma. Methods iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and com...
4 Citations Source Cite
Published on Feb 1, 2018in Transfusion and Apheresis Science 1.75
Emre Tekgündüz8
Estimated H-index: 8
,
Mehmet Yilmaz24
Estimated H-index: 24
(University of Gaziantep)
+ 25 AuthorsIrfan Kuku10
Estimated H-index: 10
(İnönü University)
Abstract Thrombotic microangiopathies (TMAs) are rare, but life-threatening disorders characterized by microangiopathic hemolytic anemia and thrombocytopenia (MAHAT) associated with multiorgan dysfunction as a result of microvascular thrombosis and tissue ischemia. The differentiation of the etiology is of utmost importance as the pathophysiological basis will dictate the choice of appropriate treatment. We retrospectively evaluated 154 (99 females and 55 males) patients who received therapeutic...
Source Cite
Published on Oct 1, 2018in Journal of Laboratory Physicians
Serife Medeni Solmaz1
Estimated H-index: 1
,
Ozcan Uzun + 8 AuthorsMehmet Ali Özcan13
Estimated H-index: 13
(Dokuz Eylül University)
BACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. MATERIALS AND METHODS: We retrospectively examined the PLR, NLR, and MLR in a cohort of 186 newly diagnosed multiple myeloma (MM) patients. This study investigated the prognostic relevance of NLR, PLR, and MLR in MM patients. NLR, PLR, and MLR were ca...
Source Cite
Published on Jun 20, 2018in Turkish Journal of Hematology 0.65
Serife Solmaz Medeni1
Estimated H-index: 1
,
Doğuş Türkyılmaz + 8 AuthorsInci Alacacioglu7
Estimated H-index: 7
Source Cite
Published on Oct 12, 2018in Leukemia 10.02
Graeme Fraser15
Estimated H-index: 15
(McMaster University),
Paula Cramer16
Estimated H-index: 16
(University of Cologne)
+ 25 AuthorsMarie-Sarah Dilhuydy14
Estimated H-index: 14
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1–45.8). Investigator-assessed median progre...
1 Citations Source Cite
Published on Nov 29, 2018in Blood 15.13
Carol Moreno24
Estimated H-index: 24
(Autonomous University of Barcelona),
Richard Greil50
Estimated H-index: 50
+ 16 AuthorsIan W. Flinn53
Estimated H-index: 53
(Sarah Cannon Research Institute)
Background : Ibrutinib (ibr), a first-in-class, once-daily inhibitor of Bruton9s tyrosine kinase, is approved in the US and EU for patients (pts) with CLL and allows for treatment without chemotherapy. Standard of care for first-line CLL in older pts or those with comorbidities includes single-agent ibr and chemoimmunotherapy (CIT) with chlorambucil (clb) plus anti-CD20 therapy. As the addition of obinutuzumab (G) to clb provides superior efficacy over clb alone or rituximab-G, we investigated t...
1 Citations Source Cite
Serife Medeni Solmaz1
Estimated H-index: 1
,
Selda Kahraman1
Estimated H-index: 1
(Medical Park)
+ 8 AuthorsBulent Undar11
Estimated H-index: 11
(Dokuz Eylül University)
Peripheral blood is the prefered source for hematopoietic stem cells for hematopoietic stem cell transplantation. The efficiency of peripheral blood stem cell (PBSC) collection can vary among devices. In this study we aimed to compare feasibility and effectivity of apheresis procedures of the different systems. Two apheresis systems [Com.Tec (Fresenius Healthcare) and Spectra Optia (Caridian BCT)] were used in our center for the collection of PBSCs for autologous and allogeneic transplantation. ...
Source Cite
12345678910